Ge Long Hui·2025-10-17 10:41Core Viewpoint - Fosun Pharma's subsidiary, Fosun Kerry, is set to receive a total investment of 600 million yuan from the Shenzhen Biopharmaceutical Industry Fund as part of its Series A financing round, aimed at enhancing the company's growth and retaining key talent [1] Group 1: Financing and Investment - The Shenzhen Biopharmaceutical Industry Fund plans to invest a total of 600 million yuan in Fosun Kerry, contributing to a maximum of 524.44 million yuan in new registered capital [1] - A total of 14 participants, including current directors and core management of Fosun Kerry, will invest 3.525 million yuan through a co-investment platform, contributing to a total of 3.081 million yuan in new registered capital [1] Group 2: Equity Incentive Plan - To motivate and retain key personnel crucial for Fosun Kerry's business growth, the company will implement an equity incentive plan approved by both the board of directors and the shareholders' meeting [1] - The incentive plan will allow for the issuance of equity rights amounting to no more than 93.22 million yuan in registered capital, with the first batch not exceeding 76.18 million yuan [1] Group 3: Shareholding Structure - Following the completion of the financing, co-investment, and equity incentive plan, the group's shareholding in Fosun Kerry will decrease from approximately 97.78% to a maximum of 77.10%, while still maintaining control over the subsidiary [2]